Metraipolis › archive › dc_e3cf44d81963
Neoadjuvant almonertinib as a bridging strategy to surgery in resectable lung cancer with active COVID-19: a case report — Europe PMC PMID:42131806
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42131806
- DOI
- 10.3389/fphar.2026.1808763
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T01:51:22.779Z
- SHA-256 of the archived text
006880953ef2d19842f6914fec2654680ee0f9d992090d0660b9533ec7910375- Stable URL of this page
https://metraipolis.com/documento/dc_e3cf44d81963
How to cite
Neoadjuvant almonertinib as a bridging strategy to surgery in resectable lung cancer with active COVID-19: a case report — Europe PMC PMID:42131806 — Europe PMC (en), https://europepmc.org/article/MED/42131806 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e3cf44d81963 (Metraipolis archive dc_e3cf44d81963, sha256 006880953ef2d19842f6914fec2654680ee0f9d992090d0660b9533ec7910375)
BibTeX
@misc{dce3cf44d81963,
title = {Neoadjuvant almonertinib as a bridging strategy to surgery in resectable lung cancer with active COVID-19: a case report — Europe PMC PMID:42131806},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42131806},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e3cf44d81963; sha256 006880953ef2d19842f6914fec2654680ee0f9d992090d0660b9533ec7910375},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42131806. Agents can read the archived copy with the MCP tool read_document.